Opaleye Management Inc.
In its 13F for Q3 2024 (holdings as of September 30, 2024, filed November 14, 2024), Opaleye Management Inc. reported 42 stock positions worth $591.4 million. Its top holding was Harrow (HROW) at 30.3% of the portfolio, followed by TG Therapeutics (TGTX, 9.0%) and Ocular Therapeutix (OCUL, 7.4%). Compared with Q2 2024, it opened 6 new positions, sold out of 13, added to 11 and reduced 18. The biggest buy was Codexis (CDXS, shares +154%) and the biggest sale Catalyst Pharmaceuticals (CPRX, shares −82%).
- Most Recent 13F
- Q2 2026
- Location
- BOSTON, MA
- CIK
- 0001595855
- Portfolio Value
- $591.4M (Q3 2024)
- SEC Filing
- 0001493152-24-045811 ↗ filed Nov 14, 2024
Holdings Value
Holdings 42 stocks · $591.4M
| HROW Harrow Inc. | 30.33% | 3,990,000 | $179.4M | No change |
| TGTX TG Therapeutics Inc. | 9.02% | 2,280,000 | $53.3M | No change |
| OCUL Ocular Therapeutix Inc. | 7.39% | 5,025,000 | $43.7M | Reduce -5.3% |
| ARVN Arvinas Inc. | 5.23% | 1,255,000 | $30.9M | Add +126.1% |
| CDXS Codexis Inc. | 4.57% | 8,770,000 | $27.0M | Add +153.8% |
| RYTM Rhythm Pharmaceuticals Inc. | 4.43% | 500,000 | $26.2M | Reduce -2.9% |
| KROS Keros Therapeutics Inc. | 3.88% | 395,276 | $23.0M | Add +7.6% |
| IMNM Immunome Inc. | 3.06% | 1,237,500 | $18.1M | Add +12.2% |
| LQDA Liquidia Corp. | 2.87% | 1,698,142 | $17.0M | Add +422.5% |
| ETON Eton Pharmaceuticals Inc. | 2.82% | 2,780,000 | $16.7M | Add +16.1% |
| EWTX Edgewise Therapeutics Inc. | 2.36% | 522,500 | $13.9M | Reduce -9.9% |
| CRGX Cargo Therapeutics Inc. | 2.00% | 541,437 | $11.8M | Reduce -2.6% |
| APLT Applied Therapeutics Inc. | 1.90% | 1,320,000 | $11.2M | Reduce -21.4% |
| PCVX Vaxcyte Inc. | 1.64% | 85,000 | $9.7M | No change |
| NRIX Nurix Therapeutics Inc. | 1.60% | 420,000 | $9.4M | Add +0.3% |
| SLRN Acelyrin Inc. | 1.58% | 1,893,660 | $9.3M | Add +19.9% |
| TRVI Trevi Therapeutics Inc. | 1.45% | 2,567,990 | $8.6M | Reduce -2.9% |
| BDSX Biodesix Inc. | 1.18% | 3,815,000 | $7.0M | Reduce -5.1% |
| DNA Ginkgo Bioworks Holdings Inc. | 1.13% | 820,202 | $6.7M | New |
| JSPR Jasper Therapeutics Inc. | 1.12% | 353,500 | $6.6M | Reduce -9.8% |
| XOMA Xoma Royalty Corporation | 1.12% | 250,000 | $6.6M | No change |
| NUVL Nuvalent Inc. Class A | 1.11% | 64,000 | $6.5M | Add +7.9% |
| NAMS Newamsterdam Pharma Co. NV | 0.94% | 335,000 | $5.6M | Add +6.3% |
| URGN Urogen Pharma Ltd. | 0.87% | 404,100 | $5.1M | Reduce -1.9% |
| PTGX Protagonist Therapeutics Inc. | 0.80% | 105,000 | $4.7M | No change |
| CYTK Cytokinetics Inc. | 0.67% | 75,300 | $4.0M | Reduce -62.1% |
| GOSS Gossamer Bio Inc. | 0.63% | 3,665,010 | $3.7M | Reduce -6.3% |
| ZNTL Zentalis Pharmaceuticals Inc. | 0.60% | 967,000 | $3.6M | New |
| TARA Protara Therapeutic Inc. | 0.52% | 1,681,154 | $3.1M | Reduce -27.0% |
| RZLT Rezolute Inc. | 0.38% | 466,563 | $2.3M | New |
| CPRX Catalyst Pharmaceuticals Inc. | 0.38% | 112,500 | $2.2M | Reduce -82.4% |
| ABCL Abcellera Biologics Inc. | 0.35% | 800,000 | $2.1M | Add +300.0% |
| LYEL Lyell Immunopharma Inc. | 0.33% | 1,395,000 | $1.9M | Reduce -16.5% |
| ALLK Allakos LLC | 0.27% | 2,407,600 | $1.6M | Reduce -13.4% |
| RLMD Relmada Therapeutics Inc. | 0.26% | 480,000 | $1.6M | Reduce -20.0% |
| PEPG Pepgen Inc. | 0.26% | 179,200 | $1.5M | New |
| RVNC Revance Therapeutics Inc. | 0.24% | 275,000 | $1.4M | New |
| SYRS Syros Pharmaceuticals Inc. | 0.24% | 654,943 | $1.4M | Reduce -24.3% |
| AEROVATE THERAPEUTICS INC | 0.16% | 440,000 | $920K | No change |
| RGLS Regulus Therapeutics Inc. | 0.14% | 535,000 | $840K | Reduce -63.7% |
| IBIO Ibio Inc. | 0.14% | 375,000 | $833K | No change |
| ADGM Adagio Medical Holdings Inc. | 0.05% | 110,571 | $285K | New |
Other holdings (2): bonds, preferreds, convertibles and warrants · $8.1M (not counted above)
| Security | Class | Shares / Principal | Value | Change |
|---|---|---|---|---|
| GOSSAMER BIO INC (GOSS 5 06/01/27) | NOTE 5.000% 6/0 · principal | 8,000,000 | $4.2M | No change |
| KARYOPHARM THERAPEUTICS (KPTI 3 10/15/25) | NOTE 3.000%10/1 · principal | 6,000,000 | $4.0M | No change |
Total filed on the 13F, all lines: $599.6M.
Portfolio Sells Q2 2024 → Q3 2024
| CPRX Catalyst Pharmaceuticals Inc. | Reduce -82.4% | 0.38% | −1.93 |
| CYTK Cytokinetics Inc. | Reduce -62.1% | 0.67% | −1.83 |
| FDMT 4D Molecular Therapeutics Inc. | Sold out | 0.00% | −1.69 |
| IOVA Iovance Biotherapeutics Inc. | Sold out | 0.00% | −1.67 |
| NTLA Intellia Therapeutics Inc. | Sold out | 0.00% | −1.13 |
| OCUL Ocular Therapeutix Inc. | Reduce -5.3% | 7.39% | −1.05 |
| JSPR Jasper Therapeutics Inc. | Reduce -9.8% | 1.12% | −0.95 |
| SYRS Syros Pharmaceuticals Inc. | Reduce -24.3% | 0.24% | −0.80 |
| URGN Urogen Pharma Ltd. | Reduce -1.9% | 0.87% | −0.74 |
| LXRX Lexicon Pharmaceuticals Inc. | Sold out | 0.00% | −0.73 |
| TARA Protara Therapeutic Inc. | Reduce -27.0% | 0.52% | −0.71 |
| SVRA Savara Inc. | Sold out | 0.00% | −0.67 |
| VTYX Ventyx Biosciences Inc. | Sold out | 0.00% | −0.64 |
| VSTM Verastem Inc. | Sold out | 0.00% | −0.63 |
| RYTM Rhythm Pharmaceuticals Inc. | Reduce -2.9% | 4.43% | −0.49 |
| RGLS Regulus Therapeutics Inc. | Reduce -63.7% | 0.14% | −0.47 |
| FULC Fulcrum Therapeutics Inc. | Sold out | 0.00% | −0.41 |
| TRVI Trevi Therapeutics Inc. | Reduce -2.9% | 1.45% | −0.38 |
| ALLK Allakos LLC | Reduce -13.4% | 0.27% | −0.38 |
| KPTI Karyopharm Therapeutics Inc. | Sold out | 0.00% | −0.29 |
| BDSX Biodesix Inc. | Reduce -5.1% | 1.18% | −0.25 |
| LYEL Lyell Immunopharma Inc. | Reduce -16.5% | 0.33% | −0.24 |
| GOSS Gossamer Bio Inc. | Reduce -6.3% | 0.63% | −0.19 |
| PMVP PMV Pharmaceuticals Inc. | Sold out | 0.00% | −0.18 |
| DSGN Design Therapeutics Inc. | Sold out | 0.00% | −0.16 |
| RLMD Relmada Therapeutics Inc. | Reduce -20.0% | 0.26% | −0.16 |
| CRGX Cargo Therapeutics Inc. | Reduce -2.6% | 2.00% | −0.12 |
| ALGS Aligos Therapeutics Inc. | Sold out | 0.00% | −0.10 |
| EWTX Edgewise Therapeutics Inc. | Reduce -9.9% | 2.36% | −0.07 |
| RENEO PHARMACEUTICALS INC | Sold out | 0.00% | −0.06 |
| APLT Applied Therapeutics Inc. | Reduce -21.4% | 1.90% | +0.07 |
Portfolio Buys Q2 2024 → Q3 2024
| CDXS Codexis Inc. | Add +153.8% | 4.57% | +2.08 |
| LQDA Liquidia Corp. | Add +422.5% | 2.87% | +1.96 |
| ARVN Arvinas Inc. | Add +126.1% | 5.23% | +1.79 |
| DNA Ginkgo Bioworks Holdings Inc. | New | 1.13% | +1.13 |
| ETON Eton Pharmaceuticals Inc. | Add +16.1% | 2.82% | +0.99 |
| ZNTL Zentalis Pharmaceuticals Inc. | New | 0.60% | +0.60 |
| RZLT Rezolute Inc. | New | 0.38% | +0.38 |
| PEPG Pepgen Inc. | New | 0.26% | +0.26 |
| RVNC Revance Therapeutics Inc. | New | 0.24% | +0.24 |
| ABCL Abcellera Biologics Inc. | Add +300.0% | 0.35% | +0.21 |
| NUVL Nuvalent Inc. Class A | Add +7.9% | 1.11% | +0.06 |
| ADGM Adagio Medical Holdings Inc. | New | 0.05% | +0.05 |
| KROS Keros Therapeutics Inc. | Add +7.6% | 3.88% | −0.03 |
| SLRN Acelyrin Inc. | Add +19.9% | 1.58% | −0.04 |
| IMNM Immunome Inc. | Add +12.2% | 3.06% | −0.04 |
| NRIX Nurix Therapeutics Inc. | Add +0.3% | 1.60% | −0.44 |
| NAMS Newamsterdam Pharma Co. NV | Add +6.3% | 0.94% | −0.47 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 58 | $1.1B | LQDA, ETON, HROW, IRON, URGN |
| Q1 2026 | 54 | $759.2M | HROW, LQDA, ETON, SLGL, RYTM |
| Q4 2025Amended | 54 | $757.9M | HROW, LQDA, ETON, RYTM, APGE |
| Q3 2025 | 42 | $702.7M | HROW, ETON, LQDA, RYTM, IMNM |
| Q2 2025Amended | 39 | $483.6M | HROW, ETON, IMNM, SNWV, LQDA |
| Q1 2025 | 43 | $438.3M | HROW, ETON, SNWV, LQDA, RYTM |
| Q4 2024 | 37 | $560.7M | HROW, TGTX, CDXS, ETON, OCUL |
| Q3 2024 | 42 | $591.4M | HROW, TGTX, OCUL, ARVN, CDXS |
| Q2 2024 | 49 | $430.0M | HROW, TGTX, OCUL, RYTM, KROS |
| Q1 2024Amended | 51 | $455.6M | OCUL, HROW, TGTX, KROS, RYTM |